WILLIAM E TRUOG, MD
Medical Practice at Gillham Rd, Kansas City, MO

License number
Missouri 103082
Category
Medical Practice
Type
Neonatal-Perinatal Medicine
License number
Missouri 04-24623
Category
Medical Practice
Type
Neonatal-Perinatal Medicine
Address
Address
2401 Gillham Rd, Kansas City, MO 64108
Phone
(816) 234-3592

Personal information

See more information about WILLIAM E TRUOG at radaris.com
Name
Address
Phone
William Truog, age 77
1020 W 67Th Ter, Kansas City, MO 64113
(816) 536-3546
William E Truog, age 48
4301 Madison Ave, Kansas City, MO 64111
William E Truog, age 77
1020 67Th Ter, Kansas City, MO 64113
(816) 523-7847
(816) 361-1680
William E Truog, age 77
1020 67Th St, Kansas City, MO 64113
(816) 523-7847
(816) 361-1680

Organization information

See more information about WILLIAM E TRUOG at bizstanding.com

Children's Mercy Hospital - William E Truog MD

2401 Gillham Rd, Kansas City, MO 64108

Categories:
Government Contractors, Physicians & Surgeons
Phone:
(816) 234-3595 (Phone)

Professional information

See more information about WILLIAM E TRUOG at trustoria.com
William Edward Truog Photo 1
William Edward Truog, Kansas City MO

William Edward Truog, Kansas City MO

Specialties:
Pediatrics, Neonatal-Perinatal Medicine, Maternal & Fetal Medicine, Radioisotopic Pathology
Work:
2401 Gillham Road
2401 Gillham Rd, Kansas City, MO 64108 Truman Medical Center Lakewood
2301 Holmes St, Kansas City, MO 64108 Childrens Mercy
5808 W 110Th St, Leawood, KS 66211
Education:
University of Chicago (1973)


William Truog Photo 2
Physician At Children's Mercy Hospital

Physician At Children's Mercy Hospital

Location:
Kansas City, Missouri Area
Industry:
Hospital & Health Care


William Truog Photo 3
Attenuation Of Hyperoxia-Induced Cell Death With Mitochondrial Aldehyde Dehydrogenase

Attenuation Of Hyperoxia-Induced Cell Death With Mitochondrial Aldehyde Dehydrogenase

US Patent:
2008005, Mar 6, 2008
Filed:
Jun 18, 2007
Appl. No.:
11/764761
Inventors:
Dong Xu - Kansas City MO, US
William Truog - Kansas City MO, US
Assignee:
THE CHILDREN'S MERCY HOSPITAL - Kansas City MO
International Classification:
A61K 31/70, A61P 11/00, C12N 15/00, C12N 15/87, C12N 5/06
US Classification:
514044000, 435320100, 435325000, 435371000, 435375000, 435455000
Abstract:
Oxygen toxicity is one of the major risk factors in the development of the chronic lung disease or bronchopulmonary dysplasia in premature infants. Using proteomic analysis, we discovered mitochondrial aldehyde dehydrogenase (mtALDH or ALDH2) was down-regulated in neonatal rat lung after hyperoxic exposure. To study the role of mtALDH in hyperoxic lung injury, we overexpressed mtALDH in human lung epithelial cells (A549) and found that mtALDH significantly reduced hyperoxia-induced cell death. Compared to control cells (Neo-A549), the necrotic cell death in mtALDH overexpressing cells (mtALDH-A549) decreased from 25.3% to 6.5%, 50.5% to 9.1% and 52.4% to 15.06% after 24-, 48- and 72-hour hyperoxic exposure, respectively. The levels of intracellular and mitochondria-derived reactive oxygen species (ROS) in mtALDH-A549 cells after hyperoxic exposure were significantly lowered compared to Neo-A549 cells. mtALDH overexpression significantly stimulated extracellular signal regulated kinase (ERK) phosphorylation under normoxic and hyperoxic conditions. Inhibition of ERK phosphorylation partially eliminated the protective effect of mtALDH in hyperoxia-induced cell death, suggesting ERK activation by mtALDH conferred cellular resistance to hyperoxia. mtALDH overexpression augmented Akt phosphorylation and maintained the total Akt level in mtALDH-A549 cells under normoxic and hyperoxic conditions. Inhibition of PI3K activation by LY294002 in mtALDH-A549 cells significantly increased necrotic cell death after hyperoxic exposure, indicating that PI3K/Akt activation by mtALDH played an important role in cell survival after hyperoxia. Taken together, these data demonstrate that mtALDH overexpression attenuates hyperoxia-induced cell death in lung epithelial cells through reduction of ROS, activation of ERK/MAPK and PI3K/Akt cell survival signaling pathways.